Use of anagrelide for treating cancer
US11324746B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2015 |
| Grant date | May 10, 2022 |
| Priority date | — |
| Expiry date | Dec 22, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.